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Objective: To measure tissue pharmacokinetics of trovafloxacin (CP 99,219) in normal and infected animals by both 
direct tissue radioactivity measurements and positron emission tomography (PET). 
Methods: Concentrations of [18Fltrovafloxacin were measured in normal and infected rats ( n =  6/group), at 10, 30, 60, 
and 120 min after injection, by radioactivity measurements. In normal rabbits (n=  4) and rabbits with Escherichia coli 
thigh infection (n=4), tissue concentrations of drug were measured over 2 h with PET. After acquiring the final images, 
the rabbits were killed and tissue concentrations measured with PET were compared to the results of direct tissue 
radioactivity measurements. 
Results: In both species, there was rapid distribution of [18FI trovafloxacin in most peripheral organs. Peak 
concentrations of more than five times the MICSO of most Enterobacteriaceae and anaerobes (>IOO-fold for most 
organisms) were achieved in all tissues and remained above this level for >2 h. Particularly high peak concentrations 
were achieved in the kidney (>75 pg/g), liver (>I00 pg/g), blood (>40 pg/g), and lung (>I0 pg/g). Even though the 
concentration of trovafloxacin in infected muscle was reduced (p<O.OI), the peak concentration was still >4 pg/g and 
tissue levels remained above 2 pg/g for more than 2 h. Due to the lower concentrations that were achieved in the brain 
(peak -5 vg/g), it is expected that trovafloxacin will have limited central nervous system toxicity. 
Conclusion: PET with [18F] trovafloxacin is a useful technique for non-invasive measurements of tissue pharma- 
cokinetics. 
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INTRODUCTION 
Trovafloxacin, ((1 a,5~~,6a)-7-(6-amin0-3-azabicyclo 
[3.1 .O]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-l,4- 
dihydro-4-0x0- 1,8-naphthyridine-3-carboxylic acid), 
(CP 99,219) is a new fluoroquinolone antimicrobial 
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agent with potent and broad-spectrum in vitro activity 
against both Gram-positive and Gram-negative 
organisms [I]. Extensive investigations comparing the 
in vitro antibacterial activity of trovafloxacin with 
that of other fluoroquinolones have been reported 
[2-81. In these studies, trovafloxacin was significantly 
more potent than standard fluoroquinolones against 
many Gram positive organism, including Streptococcus 
pneumoniae, Streptococcus pyogenes, and ciprofloxacin- 
susceptible and -resistant staphylococci. Also, trova- 
floxacin had more potent activity against anaerobic 
organisms, while retaining potency against Entero- 
bacteriaceae. In general, trovafloxacin had greater 
potency and spectrum of activity (MIc9o 5 2 p g / d )  
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than ciprofloxacin, temafloxacin and ofloxacin. Organ- 
isms for which MIC90s were L 4 p g / d  were rare, 
and included Pseudornonas aeruginosa, Bacteroides jiagilis, 
Staphylococcus haemolyticus and oxacillin-resistant 
Staphylococcus aureus. Trodoxacin has also been shown 
to have significant in vivo activity against numerous 
experimental infections [9-111. 
Studles of the tissue distribution of trodoxacin in 
laboratory animals have demonstrated rapid absorption 
fiom the gastrointestinal tract and high concentrations 
in virtually all tissues (unpublished results); however, 
detailed tissue pharmacokinetic studies have not been 
reported. In humans, concentrations of drug in body 
fluids and a small number of tissues have been measured 
[12,13], but detailed studies of tissue distribution have 
not been done. Clearly, a precise understanding of 
trovdoxacin distribution in normal and lnfected tissues 
would be of value for optimizing the use of t h i s  drug 
in the treatment of focal and systemic infections. Ths 
information would be useful in determining dosing 
schedules, as well as in predicting therapeutic efficacy 
and drug toxicity. 
Over the past several years, we have demonstrated 
that positron emission tomography (PET) is an 
extremely powerEul in vivo technique for making 
detailed pharmacokinetic measurements in both animal 
models and humans [14-211. The presence of three 
fluorine atoms in the native structure of trovafloxacin 
would make PET a useful techmque for measuring 
pharmacokinetics if a rapid method for preparing 
l8F-labeled trovafloxacin could be devised. Recently, 
we developed a method for radiolabeling trovafloxacin 
by 18F-19F exchange [22,23]. This radiolabeled drug 
is chemically identical to the native drug, except 
that one or more of the fluorine atoms are 
Since trovdoxacin undergoes a low level of in vivo 
metabolism within 6-8 h after injection in humans, the 
time fiame for most PET studies, tissue and blood 
radioactivity measurements should accurately reflect 
concentrations of intact drug (unpublished results). 
Thus, t h l s  reagent should be a useful radiopharma- 
ceutical for PET studies of tissue pharmacokinetics in 
both laboratory animals and humans. 
MATERIALS AND METHODS 
Preparation of 'OF-labeled trovafloxacin 
"F-Labeled mvdoxacin was prepared by 18F for I9F 
exchange followed by HPLC purfication. Briefly, lSF- 
prepared by the 1sO(p,n)'8F reaction [24] was dried 
azeotropically with acetonitrile in the presence of 4.0 
mg of KzCO3 and 14.6 mg of Kryptofix 2.2.2.@, 1.0 
mg of trodoxacin in 0.5 mL of dimethylsuEoxide 
(DMSO) was added and the mixture was heated at 
16OOC for 15 min. Purification was performed by 
reverse-phase HPLC (column: Vydac C18, 250 x 10 
mm, mobile phase 83 : 17 phosphate bufler, pH 4.4/ 
acetonitrile, flow rate 4 mL/min). The product was 
collected in a sterile glass vial, evaporated to dryness 
under vacuum, dissolved in sterile saline for injection 
and sterilized by filtration through a 0.22-pm 
membrane filter (Millex-GS, Millipore). This method 
routinely provided lsF-labeled trovafloxacin with 
radlochemical yields of 15-30% and radiochemical 
purity of > 97% w i h  45 min. Further details of the 
radiolabeling procedure have been described elsewhere 
1231. 
Phannacokinetics of trovafloxacin in normal 
and infected rats 
These studies were designed to evaluate the tissue 
pharmacokinetics of trodoxacin in normal and 
lnfected rats. Groups of 24 normal and infected adult 
male Sprague-Dawley rats (Charles River Breeding 
Laboratories) weighing - 200 g were injected via the 
tail vein with 18F-labeled trovafloxacin (10 mg/kg, - 50 
pCi) in 50 pL of lactate buEer, pH 4.4. At 5, 30, 60 
and 120 min afier injection, groups of six animals were 
killed and samples of blood, heart, lung, liver, spleen, 
stomach, intestine, kidney, muscle, testis, brain and 
bone were weighed and radioactivity was measured 
with a well-type gamma counter (LKB model no. 
1282, Wallac Oy, Finland). To correct for radioactive 
decay and calculate the concentration of radioactivity 
in each organ as a fraction of the injected dose, 
radioactivity in aliquots of the doses was measured in 
parallel with the tissue samples. Assuming minimal 
metabolism during the time course of the study, 
radioactivity measurements were converted to drug 
concentrations by dividing by the specific activity of 
the injected dose. Concentrations of trovafloxacin in 
the brain were corrected for intravascular drug by 
assuming a blood volume of 4.5%. The results were 
expressed as micrograms of trovafloxacin per gram of 
tissue [25]. 
Infection model 
Adult male Sprague-Dawley rats (Charles River Breed- 
ing Laboratories) weighing - 200 g were infected 
with Escherichia coli fiom a single clinical isolate. The 
organisms were grown on trypticase soy agar plates and 
individual colonies were diluted with sterile normal 
saline to produce a suspension containing - 2 x lo9 
bacteria/mL. A 0.5-mL inoculum of the suspension 
was injected into the right posterior thigh muscle and 
the animals were allowed to recover for 24 h prior to 
radiopharma-ceutical injection and tissue radioactivity 
measurements. Previous results fiom our laboratory 
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have demonstrated reproducibility of this infection 
model [16]. 
Pharmacokinetics of trovafloxacin in normal 
and infected rabbits 
These experiments were designed to evaluate the tissue 
pharmacokinetics of trovafloxacin in normal rabbits 
and rabbits with deep thigh E. coli infection by PET. 
After acquisition of the final images, the rabbits were 
sacrificed and direct tissue radioactivity measurements 
were made. All studles were performed with co- 
injection of unlabeled drug. 
Positron emission tomography 
The rabbits were positioned prone on a Plexiglas 
imaging table, with legs extended and separated &om 
the pel+. Imaging was performed with a PC-4096 
PET camera (Scanditronix AB, Sweden) [26]. The 
primary imaging parameters of the PC-4094 camera 
are: in-plane and axial resolutions of 6.0 mm FWHM, 
15 contiguous slices of 6.5-mm separation with an axial 
field of view of 9.8 cm, and a sensitivity of - 5000 
counts/s per pCi. 
All images were reconstructed with a standard 
filtered back-projection algorithm (in-plane resolution 
of 6 mm FWHM). Attenuation correction was per- 
formed with transmission data acquired with a 68Ge 
rotating pin source. The projection data were corrected 
for: non-uniformity of detector response, dead time, 
random coincidences and scattered radiation. Regions 
of interest (ROIs) were circular, with a fixed diameter 
of 16 mm. The lowest concentrations of radioactivity 
that were measured were approximately 100 n C i / d ,  
with a precision of ?5%. This corresponds to a 
quantitation limit of 0.010% injected dose/g tissue. 
The PET camera was cross-calibrated with a well 
counter by comparing the PET camera response from 
a uniform distribution of a 18F solution in a 20-cm 
cylindrical phantom with the response of the well 
counter to an aliquot of the same solution. 
Normal rabbits 
Four random-bred male New Zealand white rabbits 
weighing - 3.0 kg were studied. Immediately before 
imaging, the rabbits were anesthetized with ketamine/ 
rhompine and a left femoral arterial catheter was 
inserted for blood sampling. Each animal was placed 
in the gantry of the camera, with the area of the 
brain centered on the first slice, and [18F]-labeled 
trovafloxacin (10 mg/kg, - 5.0 mCi) was injected (over 
1 min) through a marginal ear vein. The total volume 
injected in each animal was - 2.0 mL in lactate buffer, 
pH 4.4. Imaging was started immediately after injection. 
The rabbits were imaged by indexing the scanner table 
in 9.75-cm steps to yield a total of 75 slices. The 
duration of imaging at each bed position was 1.0 min. 
Image sets were acquired starting at 0, 5, 15,30, 60 and 
120 min after injection, and arterial blood samples were 
collected at 1, 5, 10, 30, 60, 90 min and just prior 
to lulling. After acquisition of the final image, the 
animals were killed with a lethal dose of sodium 
pentobarbital. Samples of heart, lung, liver, spleen, 
ludney, prostate, brain, bone, bladder, adrenal, pituitary, 
prostate, stomach and intestine were collected and 
weighed, and radioactivity was measured with a well- 
type gamma counter. To correct for radioactive decay 
and permit calculation of radioactivity in each organ as 
a fraction of the injected dose, aliquots of the doses 
were counted in parallel. Concentrations of trova- 
floxacin in the brain were corrected for intravascular 
drug by assuming a blood volume of 4.5%. The results 
were expressed as microgram trovafloxacin per gram 
of tissue. 
Infected rabbits 
Four male New Zealand White rabbits weighing - 3.0 
kg were infected with E. coli (1 x lo1' organisms) as 
described above. The animals were allowed to recover 
for 24 h prior to imaging. 
The procedures for anesthesia, catheter placement, 
drug administration and blood sampling were identical 
to the methods used for studying normal rabbits. 
However, the imaging procedure was modified as 
follows. At 5, 10, 15, 20,25, 30, 60 and 120 min after 
injection, 5-min images of the thigh muscles were 
acquired. Between 30 and 60 min and 65 and 120 min 
after injection, whole body images were acquired 
as described above. After acquisition of the final 
images, the rabbits were killed and biodistribution was 
measured. 
Statistical methods 
The data were evaluated statistically by analysis of 
variance (ANOVA) followed by Duncan's new multiple 
range test [27]. For the biodistribution experiments in 
rats, two-way ANOVA with a linear model in which 
time after injection and infection status were the 
classification variables, was employed for each tissue: 
[Trovafloxacin] = Time + Infection + (Time x Organ). 
For the rabbit experiments, two-way ANOVA with a 
linear model in which infection status and organ were 
the classification variables was used: [Trovafloxacin] = 
Infection + Organ + (Infection x Organ). Drug con- 
centrations in normal and infected muscle were 
compared by one-way ANOVA. In order to describe 
the blood clearance of trovafloxacin in terms of a 
limited number of parameters, the time dependence of 
the blood concentration of drug was fitted to a 
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biexponential function by unweighted non-linear least 
squares using the program PROC NLIN (SAS 
Institute). All results are expressed as mean It SEM. 
RESULTS 
Pharmacokinetics of trovafloxacin in uninfected tissues of 
normal and infected rats 
Figure 1 shows the concentration of trovafloxacin 
(pg/g) in uninfected tissues of normal and infected rats 
at 5 ,  30, 60 and 120min after injection. With the 
exception of brain, relatively high concentrations of 
drug were detected in all tissues. For most tissues, the 
highest concentration of drug was measured at 5 min 
afZer injection and decreased at later times. In stomach 
and testis accumulation was delayed, while in intestine 
accumulation increased continuously over the time 
course of the study. 
For all tissues, ANOVA demonstrated significant 
main effects of time after injection; stomach p<0.05, 
all others p<O.OOOOl. Significant main effects of 
infection were observed for: blood p <  0.005, kidney 
p<O.OOOOl, intestine p<0.05, testis p<O.Ol and brain 
Significant infection-time interactions were 
not detected for any tissue. Based on the assumption 
that 100% of the drug is contained within the 
vasculature immediately after injection, within 10 min 
after injection >90% of the radiolabeled drug was 
cleared fiom blood into the tissues. 
Trovafloxacin concentrations in infected rats were 
lower in: blood (5 and 30 min, p<O.Ol); spleen (30 
min, p<O.Ol); adrenal (30 min, p<O.Ol); intestine (30 
min, pC0.05; 60min, pcO.01); and bone (5 min, 
p < 0.01). In contrast, trovafloxacin concentrations in 
infected animals were hlgher in: heart (60 min, 
p < 0.05); liver (60 min, p < 0.01); kidney (5 and 60 min, 
p<O.Ol; 120 min, p<0.05), testis (60 min, p 0 . 0 1 ;  
120 min, p<0.05); and brain (120 min, pcO.01). In 
stomach, higher concentrations were measured in 
infected rats at 60 min (p<0.05) and in normal rats at 
5 min (p<0.05). 
Peak concentrations ranged fiom >35 pg/g for 
intestine, liver and kidney to >10 pg/g in lung, spleen, 
adrenal, stomach, heart, muscle, blood and bone, to > 9 
pg/g in the spleen and heart, to > 5 pg/g in the testis, 
to <0.5 pg/g in the brain. Even at 2 h afier drug 
administration, concentrations of trovafioxacin were 
> 2 pg/g in most tissues. 
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Figure 1 Biodistribution of trovafloxacin in normal rats (open bars) and uninvolved tissues of infected rats (solid bars) at 
5, 30, 60 and 120 min after injection. The data are expressed as pg/g. The animals were infected 24 h before injection. 
Each value is the mean? SEM €or six animals. *p<0.05; **p<O.Ol. 
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Figure 2 Trovafloxacin concentrations @gig) in normal 
and infected rat muscle at 5, 30, 60 and 120 min after 
injection. The animals were infected 24 h before injection. 
Normal* indicates uninfected muscle of infected rats. Each 
value is the mean ? SEM for six animals. *p<0.05; 
**p < 0.01. 
Pharmacokinetics of trovafloxacin in infected muscle 
of rats 
Figure 2 shows the concentration (pg/g) of trova- 
floxacin in thigh muscle of normal and infected rats at 
5 ,  30, 60 and 120 min after injection. In both normal 
and infected muscle, the highest concentration of drug 
was measured at 5 min after injection and decreased 
thereafter. ANOVA demonstrated significant main 
effects of time (p<O.OOOl), infection (pCO.01) and 
infection-time interaction (p<O.OOOOl).  At 5 min, the 
trovafloxacin concentration was greatest in uninfected 
muscle of infected animals (p<O.Ol), and the 
concentration in infected muscle was greater than in 
muscle of uninfected animals (p<O.Ol). At 60 and 120 
min, the concentration of trovafloxacin in infected 
muscle was higher than in uninfected muscle of 
infected animals (p<O.Ol and p<O.O5) but not 
significantly different horn that in normal animals. At 
1 and 2 h after administration, drug concentrations in 
infected muscle were > 4 pg/g and > 2 pg/g. 
PET imaging and biodistribution of trovafloxacin in rabbits 
Figure 3 shows representative PET images of a rabbit 
Figure 3 Sagittal and coronal PET images of a rabbit 30 min after injection of ['*F]trovafloxacin plus 10 mg/kg unlabeled 
trovafloxacin. Drug concentrations are indicated by the color bar. 
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Figure 4 Blood clearance of trova0oxacin in normal 
and infected rabbits. Results &om individual animals are 
not indicated. Each value is the mean t SEM for four 
animals. The data were well described by biexponential 
fimctions. 
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30 m h  afier injection of ['*F]trovafloxacin with 10 
mg/kg of unlabeled drug. From these images, it is 
apparent that relatively high concentrations of trova- 
floxacin are achieved in all tissues, with the exception 
of brain. In most tissues, high levels of accumulation 
were achieved within 20min afier injection and 
decreased over the next 100 min. Figure 4 shows that 
blood decline of trodoxacin in normal and infected 
rabbits is well described by biexponential functions 
(fitting parameters expressed as value 2 SD): 
Normal: [Trovafoxacin] = (31.39+0.80)e -(0.208*0.013)r + 
(11.46 20.57)e -(o~006s~~ooo8)f R2=0.95 
Infected [Tmvafloxacin] = (25.75k 1.80)e -(0.175f0.03)f + 
(15.642 1.30)~ -(0.~52*0.0012tt R2=0.96 
Although infection did not have a significant 
effect on the rate constants for the a or p phases of 
trovafloxacin clearance ( p  > O.l ) ,  the contribution of 
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Figure 5 Tissue accumulation curves of trovdoxacin in n o r d  ( ~ 4 )  and infected (n=4) rabbits. Since there was no 
sigmficant difference in drug concentrations between uninfected tissues of normal and infected animals, these data were 
pooled for analysis and each value represents the meant SEM for eight animals. Concentrations were measured by PET. 
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the a phase was decreased and the contribution of 
the p phase was increased (p>O.Ol). The apparent 
volumes of distribution (Vd) of drug in normal and 
infected animals were 700.2 e15.7 and 724.9 238.9 
mL (p=NS). 
Figure 5 illustrates tissue accumulation curves for 
trovafloxacin in normal (n=4) and infected (n=4) 
rabbits measured by PET. Since there was no significant 
Merence in drug concentrations between uninfected 
tissues of normal and infected animals, these data 
were pooled. Peak concentrations of trovafloxacin 
were: >75 pg/g in hdney (not shown); >lo0 pg/g in 
liver; >40 pg/g in blood; >10 pg/g in lung; >5 pg/g 
in brain; > 8 pg/g in uninfected muscle. The concen- 
tration of trovafloxacin in infected muscle was signi- 
ficantly (p<O.Ol) lower than in normal muscle at all 
imaging times; however, peak concentration was still 
>4 pg/g and remained at >2 pg/g at 2 h after injection. 
Figure 6 shows the biodistribution of trovailoxacin in 
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uninfected tissues of normal and infected rabbits at 2 h 
after injection. ANOVA demonstrated si&icant main 
effects of tissue (p<O.OOOl) and infection (p<0.005). 
However, tissue-infection interaction was not signi- 
ficant ( p 0 . 4 )  and differences in drug concentration 
were not detected in any specific tissue. Even at 2 h 
post-administration, concentrations of > 2 pg/g were 
present in most tissues (>8 pg/g in kidney, liver, 
gastrointestinal tract, lung, prostate, stomach, bladder 
and spleen; brain concentrations were >0.4 pg/g). 
Figure 7 shows the concentrations of trovafloxacin in 
normal and infected rabbit muscle. Although drug 
concentration was lower in infected muscle, in contrast 
to the imaging results, ANOVA failed to demonstrate 
a significant effect. In general, trovafloxacin concen- 
trations determined by direct measurements of radio- 
activity in tissue samples were in excellent agreement 
with the PET results. 
KIDNEY ( x  0.33) 
T T 
L 
Figure 6 Biodistribution of trovafloxacin in normal rabbits and rabbits with deep thigh E. coli infections at 2 h after 
injection. The data are expressed as pg/g. The animals were infected 24 h before injection. Each value is the mean * SEM 
for four animals. Concentrations were determined by direct tissue radioactivity measurements. 
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Figure 7 Trovafloxacin concentrations (pg/g) in normal 
and infected rabbit muscle at 120 min after injection 
determined by direct tissue radioactivity measurements. 
The animals were infected 24 h before injection. Normal* 
indicates uninfected muscle of infected rabbits. Each value 
is the mean 2 SEM for four animals. 
DISCUSSION 
The pattern of distribution of trovafloxacin in normal 
and infected rats determined with ['8F]trovafloxacin 
is generally consistent with the results of whole 
body autoradographic studies at one time point after 
injection of 14C-labeled drug (unpublished results). 
Also, the pattern of distribution of trovafloxacin in 
rabbits measured by both PET and direct radioactivity 
measurements was s d a r  to that seen with rats. The 
monotonic decrease in trovafloxacin concentration in 
kidney and liver is most probably related to the fact 
that these are clearance organs. Similarly, the rapidly 
decreasing concentration of drug in lung and muscle 
may be due to rapid equilibration in these organs. The 
low level of trovafloxacin accumulation in bone is 
consistent with its proposed mechanism of metabolism 
via conjugation with minimal defluorination [28,29]. 
This observation supports the utility of ['8F]trova- 
floxacin prepared by I8F-l9F exchange for pharmaco- 
kinetic studies [23]. In rats, at 5 min after injection, 
trovafloxacin concentration in infected muscle was 
greater than in muscle of uninfected amnals but lower 
than in uninfected muscle of infected animals. At 30 
min, similar concentrations were measured in all three 
tissues, while at 60 and 120 min, concentrations in 
infected muscle and muscle of uninfected rats were 
simdar to each other but greater than concentrations in 
u d e c t e d  muscle of dected animals. In contrast, drug 
concentrations in u d e c t e d  muscle of infected rabbits 
were greater than in infected muscle or muscle of 
uninfected arurnals. Currently, we have no explanation 
for these differences between rats and rabbits. 
Since the major purpose of this study was to 
develop and validate a PET method that could be 
applied to humans, it is fortunate that the primary mute 
of trovafloxacin metabolism in humans is conjugation, 
which does not s e c t  the 18F labels. For human studies, 
the spatial resolution and quantitative nature of PET 
measurements will allow the evaluation of drug 
distribution in s m a l l  volumes of tissue. Our previous 
experience with 18F-labeled antimicrobial agents has 
demonstrated the validity of this approach [14-211. 
Based on the current biodistribution data, p rehna ry  
Medical Internal Radiation Dose (MIRdose) calcula- 
tions [30] indicate that - 20 mCi of [18F]trovafloxacin 
can be administered to humans without delivering a 
radiation burden in excess of 20 mGy to any organ 
(unpublished results). With this dose of racloactivity, 
pharmacokinetics can be studied over 8 to 10 h by PET. 
The use of PET to study pharmacokinetics has 
many advantages over more conventional techques. 
Although changes in drug concentrations in tissues 
could be determined by radioactivity measurements of 
excised tissues or quantitative autoradiography using 
many animals, PET allows multiple measurements in 
the same subject at Herent  times and in a variety of 
physiologic or pathologic states. A major benefit of 
PET is the quantitative nature of the measurement. 
Even more importantly, PET is the only non-invasive 
technique that can be used to measure tissue pharma- 
cokinetics quantitatively in humans. 
The concentrations of trovafloxacin achieved in 
normal and infected tissues of rats and rabbits appear 
promising when compared to the sensitivity of a wide 
range of microorganisms to trovafloxacin. Thus whrle 
the MIC90s for virtually all the Entembacteriaceae 
and anaerobes are <0.5 p g / d  [2,4-8,311, peak con- 
centrations of drug are well over 5 pg/g in all extra- 
cranial tissues, with sustained concentrations above the 
MIC90s in virtually all tissues for at least 2 h. In 
particular, the animal studies performed thus far suggest 
that this drug should be especially useful in the 
treatment of gastrointestinal, urinary tract, hepato- 
biliary and pulmonary infections, and should have 
promise in the treatment of infections of many other 
sites. Even though the concentration of trovatloxacin 
in infected muscle was reduced (p<O.Ol), the peak 
concentration was s t i l l  > 4  pg/g and tissue levels 
remained above 2 pg/g for more than 2 h. The low 
concentrations of drug achieved in the brain indicate 
that central nervous system toxicity, an important 
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issue with fluoroquinolones, may not be a significant 
problem. However, since these concentrations are 
higher than the MIC90 for S. pneumoniae (- 0.2 
pg/mL), it is possible that trovafloxacin may be effective 
for treating central nervous system infections caused by 
this organism [32,33]. 
In summary, we have developed a method for 
preparing ['8F]trovafloxacin and demonstrated its 
applicability for the non-invasive measurement of tissue 
pharmacokinetics by PET. The studies presented here 
demonstrate that there is rapid accumulation of drug in 
most tissues and the concentrations achieved are well 
above the MIC90s of most relevant pathogens. These 
results indicate that fiture PET studies in human 
subjects will yield valuable insights into the clinical 
application of this important new drug. 
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